Indivior PLC (LON:INDV – Get Free Report)’s share price was down 34.4% during mid-day trading on Tuesday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 2,350 to GBX 1,500. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Indivior traded as low as GBX 701.50 ($8.99) and last traded at GBX 775.24 ($9.93). Approximately 23,030,988 shares changed hands during trading, an increase of 3,388% from the average daily volume of 660,225 shares. The stock had previously closed at GBX 1,181 ($15.13).
Indivior Trading Up 1.7 %
The business has a fifty day moving average of GBX 1,310.67 and a 200-day moving average of GBX 1,415.90. The company has a debt-to-equity ratio of 2,790.00, a quick ratio of 1.52 and a current ratio of 0.93. The company has a market capitalization of £1.07 billion, a P/E ratio of 26,000.00, a PEG ratio of -5.57 and a beta of 0.06.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- 3 Tickers Leading a Meme Stock Revival
- This Stock’s Price Shifts Into High Gear With Analyst Upgrades
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- AI Boosts Glass Tech Leader Stock: Shares Up 75% and More to Come
- Low PE Growth Stocks: Unlocking Investment Opportunities
- AI Partnership Boosts This Top Tech Stock: Ready for More Gains?
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
